Introduction
============

Acquired carbapenemases in *Enterobacteriaceae* have been reported extensively worldwide \[[@r1]\]. Asymptomatic carriage and infection caused by carbapenemase-producing *Enterobacteriaceae* (CPE) isolates currently raise major public health concern for individual therapeutic management and for collective infection control \[[@r2]\]. The prevalence of carbapenem resistance and the types of carbapenemases found in Europe vary between countries \[[@r3],[@r4]\] and since 2010 an increase in the isolation rate of CPE from various European countries has been reported \[[@r5]\]. In Belgium, the last multicentric survey performed among 24 hospitals in 2012 \[[@r6]\] showed an overall proportion of 3.5% of carbapenem non-susceptible *Enterobacteriaceae* (CNSE) and an estimated proportion of 0.28% of CPE among *Enterobacteriaceae* isolates using Clinical and Laboratory Standards Institute (CLSI) carbapenems susceptibility breakpoints as screening criteria \[[@r7]\]. Further, one third (8/24) of the participating hospital laboratories had isolated one or several CPE isolates in their institution during the study period \[[@r6]\]. The national surveillance programme of CPE established in January 2012 by the Scientific Public Health Institute together with the National Reference Centre showed a yearly increase from 2012 to 2014 of number and proportion of hospital-based and of private laboratories reporting confirmed CPE \[[@r8]\].

The present cross-sectional survey aimed to determine the evolution of the proportion of CNSE and of CPE among *Enterobacteriaceae* isolates collected in Belgian hospitals and to gain insight of their epidemiology outside hospitals in specimens collected from community outpatients sent to private laboratories.

Methods
=======

Study design, inclusion criteria and testing at participating centres
---------------------------------------------------------------------

In 2015, 24 hospital-based laboratories that participated to the survey in 2012 serving around 25% of all acute hospitals in Belgium (hospital size ranging from 288 to 1,803 beds; median number of 747 beds per hospital) were requested to collect consecutively 200 *Enterobacteriaceae* isolates cultured from clinical samples of hospitalised patients (screening samples such as stools or rectal swabs were excluded) over a period of 2 months (i.e. from September to November). Only the first isolate of the same species per patient was included. The sample collection, culture and bacterial identification were performed using local procedures. In addition, 10 private laboratories (representing around 20% of all private laboratories in Belgium) serving general practitioners participated as well using the same study protocol and were asked to test 200 *Enterobacteriaceae* isolates cultured from clinical samples of outpatients in the community.

All isolates were tested locally for susceptibility to meropenem (10-µg) and ertapenem (10-µg) by disk diffusion method according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines \[[@r9]\] and all inhibition zone diameters were recorded. All testing materials purchased from the same manufacturer (BioRad, Marnes-la-Coquette, France) had the same manufacture batch number in order to avoid inter-lot variations. *Escherichia coli* ATCC 25922 was tested as quality control strain in each centre during the survey.

*Enterobacteriaceae* isolates showing a decreased inhibition zone diameters according to EUCAST screening breakpoints \[[@r10]\] to any of the two carbapenems disks (ertapenem \< 25 mm and/or meropenem \< 25 mm) were defined as putative CPE (PCPE) and had to be referred to the reference laboratory.

Characterisation of resistance mechanisms and data analysis
-----------------------------------------------------------

All PCPE isolates sent to the reference laboratory were tested for carbapenemase production by the electrochemical imipenem-hydrolysis based BYG Carba test \[[@r11]\] and underwent multiplex PCR targeting *bla*~VIM~, *bla*~IMP~, *bla*~NDM~, *bla*~KPC~ and *bla*~OXA-48~ for the detection of carbapenemase encoding genes \[[@r12]\]. The PCR-positive amplicons were sequenced using an external service company (Macrogen Inc., Seoul, South Korea). The sequence obtained was compared with the genes present in GenBank and aligned with the reference gene cited at the Lahey Clinic \[[@r13]\].

For confirmed CPE isolates, minimal inhibitory concentration (MIC) values of antimicrobial agents including carbapenems were determined by broth microdilution method (Sensititre, Trek Diagnostic Systems, Cleveland, US). The MIC value of temocillin was determined by Etest method (bioMérieux, Marcy-l'Etoile, France). Susceptibility categorisation was interpreted according to EUCAST interpretative criteria \[[@r9]\] for all antimicrobial agents except temocillin (breakpoints according to Fuchs et al.) \[[@r14]\]. Colistin-resistant isolates were further tested by end-point PCR for the presence of the plasmid-mediated colistin resistance *mcr-1* gene \[[@r15]\].

The proportion of CNSE as defined by the EUCAST disk diffusion susceptibility breakpoints (ertapenem \<25 mm and/or meropenem \<22 mm) and of CPE isolates were calculated based on inhibition zone diameters of all isolates provided overall in hospitals or in private laboratories, for each centre and also by species or genus. Following the application of harmonised microbiological criteria (the ertapenem and meropenem discs zone diameters recorded in 2012 were reinterpreted using EUCAST interpretative criteria), results from 2015 were compared with those in 2012 for hospital-based laboratories.

Clonal relatedness of the carbapenemase-producing *Klebsiella pneumoniae* isolates was investigated by the DiversiLab system (bioMérieux, Marcy l'Étoile, France) using the repetitive extragenic palindromic (rep)-PCR methodology \[[@r16]\]. Isolates with \> 95% similarity were considered related.

Results
=======

In total, 4,705 and 1,991 non-duplicate *Enterobacteriaceae* isolates were screened by the 24 hospital-based and by 10 private laboratories respectively from September to November 2015. A median number of 200 isolates per laboratory was achieved and all but one centre reached \> 195 isolates screened. The distributions of origins of screened isolates were highly comparable to 2012 with urine (2,642/4,705; 56%) and medical wards (1,818/4,705; 39%) representing the principal origins of the isolates screened and the main sources of CNSE isolates in hospitals (data not shown). The highest proportion of CNSE isolates in hospitals was found in respiratory tract (36/714; 5.0%) and in the intensive care units (30/711; 4.2%). On the other hand, urinary origin (1,902/1,991; 96%) of screened isolates was as expected largely predominant in private laboratories.

The number and the proportions of CNSE according to EUCAST susceptibility criteria and of CPE among tested isolates per species are reported and compared with the 2012 study results in [Table 1](#t1){ref-type="table"}.

###### Species/group distribution and proportion of CNSE (according to EUCAST interpretative criteria) and of CPE among isolates screened by 24 hospital-based and 10 private community-serving laboratories in Belgium, 2012 (n = 4,471) and 2015 (n = 6,696)

  Species or group                          2015 survey   2012 survey                                                                              
  ----------------------------------------- ------------- ------------- --------- -------- ---------- --------------- --------- --------- -------- ----------
  Hospital-based laboratory                                                                                                                        
  *Escherichia coli*                        2,560         15            0.6       3        0.12       2,537           26        1.0       1        0.04
  *Klebsiella pneumoniae*                   629           35            5.6       18       2.86       434             36        8.3       9        2.07
  *Klebsiella oxytoca*                      216           3             1.4       2        0.93       209             3         1.4       1        0.48
  *Citrobacter* spp.                        150           7             4.7       3        2.00       150             11        7.3       0        0
  *Enterobacter* spp.                       423           61            14.4      0        0          391             118       30.2      0        0
  *Proteaceae*                              551           7             1.3       0        0          559             15        2.7       0        0
  Others                                    176           1             0.6       0        0          191             7         3.7       0        0
  **Total**                                 **4,705**     **129**       **2.7**   **26**   **0.55**   **4,471**       **216**   **4.8**   **11**   **0.25**
  Private community-serving laboratory^a^                                                                                                          
  *Escherichia coli*                        1,276         3             0.2       1        0.08       Not available                                
  *Klebsiella pneumoniae*                   275           19            6.9       8        2.91                                                    
  *Klebsiella oxytoca*                      73            3             4.1       1        1.37                                                    
  *Citrobacter* spp.                        71            2             2.8       2        2.82                                                    
  *Enterobacter* spp.                       81            10            12.3      0        0                                                       
  *Proteaceae*                              184           0             0         0        0                                                       
  Others                                    31            0             0         0        0                                                       
  **Total**                                 **1,991**     **37**        **1.9**   **12**   **0.60**                                                

CNSE: carbapenem-non-susceptible *Enterobacteriaceae*; CPE, carbapenemase-producing *Enterobacteriaceae*; EUCAST: European Committee on Antimicrobial Susceptibility Testing.

^a^ Private laboratories served general practitioners for outpatient care.

The global proportion of CNSE among clinical *Enterobacteriaceae* isolates among hospitalised patients in 2015 was 2.7% (129/4,705; 95% confidence interval (CI): 2.3--3.2%) and it ranged per centre from 0.5% (1/200) to 7.0% (14/200). Compared with the 2012 results calculated after using identical microbiological criteria (216/4,471; 4.8%; 95% CI: 4.2--5.4%), the overall proportion of clinical CNSE decreased significantly in the same hospitals (p \< 0.001 by Pearson chi-squared test). While the proportion of *Enterobacter* spp. among screened isolates in hospitals were identical between the two study periods (i.e. 9%; 423/4,705 in 2015 and 391/4,471 in 2012), the carbapenem non-susceptibility rate dropped significantly in this group from 30.2% (118/391) in 2012 to 14.4% (61/423) in 2015 (p \< 0.001) and contributed to the overall decrease of the CNSE rate in 2015.

Among ambulant patients, a total of 37 isolates from seven private laboratories would be categorised as CNSE representing a proportion of clinical CNSE isolates of 1.9% (37/1,991; 95% CI: 1.3%--2.5%) in the ambulatory setting ranging per centre from 0% to 8% (16/200). Comparing to the hospitals in which *Enterobacter* spp. accounted for nearly half of the CNSE isolates (61/129), *K. pneumoniae* represented the main CNSE species among the ambulatory isolates (19/37) since a lower proportion of *Enterobacter* spp. (4%; 81/1,991) were cultured in private laboratories. In hospitalised patients, the rate of meropenem non-susceptibility found in *K. pneumoniae* (2.5%; 16/629) remained stable in 2015 compared with 2012 (2.3%; 10/434).

Overall in 2015, 114/133 (86%) and 30/42 (71%) PCPE (using EUCAST screening cut-offs) isolates were referred from hospital-based and from private laboratories respectively to the reference laboratory and tested for the presence of carbapenemase. Considering the hospital-based and private laboratory data together, *K. pneumoniae* (26/38; 68%) and OXA-48 (28/38; 74%) were the main species and carbapenemase type respectively detected among CPE isolates in Belgium. While none of the 57 *Enterobacter* spp. isolates analysed could be confirmed as CPE, nearly half of the referred *K. pneumoniae* isolates (26/54; 48%) were confirmed as CPE (OXA-48-like, n = 17; KPC-type, n = 7; and NDM-type, n = 2). OXA-48 carbapenemase was detected in four *E. coli* isolates including one coproducing NDM enzyme, three *Citrobacter freundii*, two *C. koseri* and two *K. oxytoca* isolates. One VIM-producing *K. oxytoca* was also detected by PCR. All PCR-negative PCPE isolates did not hydrolyse imipenem by BYG Carba test, thus excluding the phenotypical expression of undetected carbapenemases by our multiplex PCR assay.

On the whole, the minimal estimated proportion of CPE was 0.55% (26/4,705; 95% CI: 0.34--0.76%) among clinical *Enterobacteriaceae* isolated from hospitalised patients and 0.60% (12/1,991; 95% CI: 0.26--0.94%) among the ambulatory patients ranging per centre from 0% (for 11 hospitals and seven private laboratories) to 3.09% (6/194; in one centre). The distribution of carbapenemase types by centre is listed in [Table 2](#t2){ref-type="table"}.

###### Carbapenemase types detected in clinical CPE isolates per health centre, Belgium, 2012 (n = 11 CPE isolates) and 2015 (n = 38 CPE isolates)

  Centre numbers                                Carbapenemase (number of isolates)   
  --------------------------------------------- ------------------------------------ ------------------
  Hospital-based laboratory                                                          
  C02                                           OXA-48 (1)                           None
  C04                                           None                                 KPC (1)
  C06                                           OXA-48 (2)                           OXA-48 (1)
  C07                                           NDM-1 (1)                            None
  C08                                           NDM-5 and OXA-181 (1), OXA-48 (1)    OXA-48 (1)
  C10                                           OXA-48 (1)                           None
  C11                                           OXA-48 (2)                           None
  C12                                           NDM-1 (1)                            KPC (1)
  C13                                           OXA-48 (2)                           OXA-48 (1)
  C14                                           KPC-2 (1), KPC-3 (1)                 KPC (2), NDM (1)
  C17                                           OXA-48 (4)                           None
  C19                                           None                                 OXA-48 (1)
  C20                                           OXA-48 (1)                           None
  C23                                           KPC-3 (3), KPC-2 (1), VIM-1 (1)      OXA-48 (2)
  C24                                           OXA-48 (2)                           None
  C01, C03, C05, C09, C15, C16, C18, C21, C22   None                                 None
  Private community-serving laboratory^a^                                            
  C26                                           OXA-48 (4)                           Not available
  C30                                           OXA-48 (6)                           
  C33                                           OXA-48 (1), KPC-3 (1)                
  C25, C27, C28, C29, C31, C32, C34             None                                 

CPE: carbapenemase-producing *Enterobacteriaceae.*

^a^ Private laboratories served general practitioners for outpatient care.

In 2015 among hospitals, while the 16 cases of OXA-48 CPE were distributed in nine different hospitals, the 6 KPC-type CPE cases were grouped within two hospitals. In the community setting, the 12 CPE isolates (dominated by OXA-48; n = 11) were found in isolates from three private laboratories.

Compared with 2012 (11/4,471, 0.25%; 95% CI: 0.10--0.39%), the overall proportion of clinical CPE in 2015 (26/4,705, 0.55%; 95% CI: 0.34--0.76%) increased significantly (p = 0.02 by Pearson chi-squared test) in the 24 surveyed hospitals and the proportion of hospitals collecting at least one clinical CPE isolate also appears to have increased from 8/24 in 2012 to 13/24 in 2015 (p value non-significant).

Based on disc diffusion with EUCAST interpretative criteria, all 38 confirmed CPE isolates in 2015 were intermediately-resistant or resistant to ertapenem disk while 16 (42%; all of OXA-48 type) were categorised as susceptible to meropenem disk. Two OXA-48-producing (one *E.* coli and one *C. koseri*) isolates had an inhibition zone to meropenem of ≥ 25 mm and would be missed if EUCAST screening breakpoint was applied using meropenem disc alone. One of these two CPE (*C. koseri*) showed additionally an ertapenem zone diameter of 24 mm and therefore would have been missed as well if the CLSI susceptibility breakpoints (ertapenem \<22 mm and/or meropenem \<23 mm) used as screening criteria in the 2012 survey were applied.

Origins and microbiological characteristics including MIC results of the 38 confirmed CPE isolates are detailed in [Table 3](#t3){ref-type="table"}.

###### Samples data of confirmed CPE isolates and broth microdilution minimum inhibitory concentration (MIC) determination to 17 antimicrobials, Belgium, 2015 (n = 38)

  Centre number   Sample origin   Hospital ward   Bacterial species   Carbapenemase    DiversiLab type^a^   Antimicrobial^b^ MICs (µg/mL)                                                                                                                        
  --------------- --------------- --------------- ------------------- ---------------- -------------------- ------------------------------- -------- ------- ------- ------- ------- -------- ------ ----- ------- ------ ------- -------- ------- ------ ------ -------
  C02             Urine           Medical         *K. pneumoniae*     OXA-48           5                    \> 1,024                        256      32      \> 32   64      64      128      4      4     2       \> 8   16      4        \> 16   \> 4   0.25   0.5
  C06             Respiratory     ICU             *K. pneumoniae*     OXA-48           3                    \> 1,024                        \> 256   16      \> 32   16      16      64       4      4     2       \> 8   16      4        4       \> 4   0.25   0.5
  C06             Urine           Medical         *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        \> 256   32      \> 32   32      16      128      4      4     2       \> 8   16      2        \> 16   \> 4   0.5    0.5
  C07             Respiratory     ICU             *K. pneumoniae*     NDM-1            Singleton            48                              \> 256   \> 64   \> 32   \> 64   64      32       \> 4   32    32      1      8       8        1       0.5    0.5    0.5
  C08             Respiratory     Medical         *E. coli*           NDM-5, OXA-181   NA                   \> 1,024                        \> 256   \> 64   \> 32   \> 64   \> 64   \> 128   \> 4   16    32      1      8       4        \> 16   \> 4   0.25   0.5
  C08             Pus             Medical         *E. coli* ^d^       OXA-48           NA                   \> 1,024                        64       0.25    1       0.5     0.5     1        1      1     0.5     \> 8   4       2        \> 16   1      0.25   4
  C10             Urine           Medical         *C. freundii*       OXA-48           NA                   \> 1,024                        \> 256   16      \> 32   16      \> 64   64       1      2     1       1      8       4        1       \> 4   0.25   0.5
  C11             Other           Other           *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        \> 256   1       1       0.5     0.5     1        \> 4   4     2       1      0.25    2        0.12    \> 4   0.25   0.5
  C11             Urine           Other           *C. freundii*       OXA-48           NA                   \> 1,024                        \> 256   2       4       2       1       1        2      4     2       \> 8   4       2        8       \> 4   2      0.5
  C12             Pus             Medical         *K. pneumoniae*     NDM-1            Singleton            \> 1,024                        \> 256   \> 64   \> 32   \> 64   64      \> 128   \> 4   32    16      \> 8   \> 32   \> 128   \> 16   2      0.25   0.5
  C13             Urine           ICU             *K. oxytoca*        OXA-48           NA                   \> 1,024                        \> 256   32      32      \> 64   4       \> 128   \> 4   4     4       1      0.25    2        2       0.5    1      0.5
  C13             Pus             Other           *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        \> 256   64      \> 32   64      64      128      \> 4   8     4       \> 8   8       2        \> 16   \> 4   1      \> 16
  C14             Respiratory     ICU             *K. pneumoniae*     KPC-2            Singleton            96                              \> 256   64      \> 32   \> 64   \> 64   \> 128   \> 4   64    \> 32   2      1       4        \> 16   1      1      8
  C14             Other           ICU             *K. pneumoniae*     KPC-3            Singleton            48                              \> 256   \> 64   \> 32   \> 64   32      \> 128   \> 4   16    8       \> 8   32      4        4       \> 4   0.25   0.5
  C17             Urine           Medical         *K. pneumoniae*     OXA-48           23                   \> 1,024                        256      1       1       0.5     0.5     1        2      4     1       1      0.25    2        16      \> 4   0.5    0.5
  C17             Urine           Medical         *K. pneumoniae*     OXA-48           23                   \> 1,024                        \> 256   32      \> 32   64      64      128      2      2     2       1      4       2        \> 16   \> 4   1      0.5
  C17             Pus             Surgery         *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        \> 256   32      \> 32   64      32      \> 128   4      4     2       1      8       2        \> 16   0.5    0.5    0.5
  C17             Urine           Medical         *K. pneumoniae*     OXA-48           23                   \> 1,024                        \> 256   16      \> 32   16      64      64       1      4     2       1      8       2        \> 16   0.5    0.5    0.5
  C20             Respiratory     Medical         *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        256      16      \> 32   32      16      64       1      2     0.5     \> 8   32      4        \> 16   \> 4   0.25   \> 16
  C23             Urine           Medical         *K. pneumoniae*     KPC-3            16                   48                              256      \> 64   \> 32   64      64      128      \> 4   32    \> 32   \> 8   \> 32   32       \> 16   \> 4   0.5    16
  C23             Pus             ICU             *K. pneumoniae*     KPC-2            Singleton            24                              256      16      16      16      16      128      \> 4   8     8       1      0.5     2        0.25    0.5    2      0.5
  C23             Pus             Medical         *K. pneumoniae*     KPC-3            16                   32                              256      64      \> 32   64      64      128      \> 4   32    \> 32   \> 8   32      32       \> 16   \> 4   1      16
  C23             Respiratory     Medical         *K. pneumoniae*     KPC-3            16                   32                              256      64      \> 32   64      64      128      \> 4   32    \> 32   \> 8   32      64       \> 16   \> 4   1      \> 16
  C23             Respiratory     Medical         *K. oxytoca*        VIM-1            NA                   256                             256      \> 64   \> 32   \> 64   16      128      0.5    8     2       1      8       8        0.5     \> 4   0.25   0.5
  C24             Blood           Other           *E. coli*           OXA-48           NA                   \> 1,024                        128      1       1       0.5     0.5     1        2      0.5   1       1      0.25    2        \> 16   \> 4   0.25   0.5
  C24             Other           Other           *C. koseri*         OXA-48           NA                   \> 1,024                        256      1       4       1       2       4        \> 4   1     1       1      1       4        0.25    \> 4   0.25   1
  C26             Urine           Ambulatory      *K. pneumoniae*     OXA-48           Singleton            768                             \> 256   2       1       0.5     0.5     1        2      8     4       1      0.5     2        0.12    0.5    0.25   1
  C26             Urine           Ambulatory      *K. oxytoca*        OXA-48           NA                   \> 1,024                        256      4       2       2       2       64       1      1     0.5     1      0.25    2        4       \> 4   0.5    0.5
  C26             Urine           Ambulatory      *K. pneumoniae*     OXA-48           5                    \> 1,024                        128      16      \> 32   32      16      64       1      0.5   0.25    \> 8   \> 32   16       \> 16   \> 4   0.25   0.5
  C26             Urine           Ambulatory      *K. pneumoniae*     OXA-48           5                    \> 1,024                        256      32      \> 32   32      64      64       4      4     4       \> 8   32      32       \> 16   \> 4   0.5    0.5
  C30             Urine           Ambulatory      *K. pneumoniae*     OXA-48           Singleton            \> 1,024                        128      1       1       0.5     0.5     1        1      0.5   0.25    1      16      4        16      0.5    0.25   0.5
  C30             Urine           Ambulatory      *C. koseri*         OXA-48           NA                   256                             16       0.25    1       0.5     0.5     1        0.25   0.5   0.25    1      0.25    2        0.12    0.5    0.25   0.5
  C30             Pus             Ambulatory      *K. pneumoniae*     OXA-48           3                    \> 1,024                        128      16      \> 32   32      32      64       2      0.5   0.5     \> 8   32      4        \> 16   \> 4   0.5    0.5
  C30             Urine           Ambulatory      *K. pneumoniae*     OXA-48           3                    \> 1,024                        \> 256   16      \> 32   16      16      32       2      2     1       \> 8   16      4        4       \> 4   0.5    0.5
  C30             Pus             Ambulatory      *K. pneumoniae*     OXA-48           3                    \> 1,024                        128      2       32      4       4       32       1      2     0.5     \> 8   16      2        2       \> 4   0.25   0.5
  C30             Urine           Ambulatory      *C. freundii*       OXA-48           NA                   \> 1,024                        256      4       16      32      0.5     32       2      4     2       4      16      32       1       0.5    0.25   0.5
  C33             Urine           Ambulatory      *E. coli*           OXA-48           NA                   512                             32       0.25    1       0.5     0.5     1        1      0.5   0.25    1      0.5     2        0.12    0.5    0.25   0.5
  C33             Urine           Ambulatory      *K. pneumoniae*     KPC-3            Singleton            32                              256      32      8       64      4       128      \> 4   8     8       1      32      32       \> 16   \> 4   0.5    0.5

*C. freundii: Citrobacter freundii; C. koseri: Citrobacter koseri;* CPE: carbapenemase-producing *Enterobacteriaceae; E. coli*: *Escherichia coli*; ICU (intensive care unit); *K. pneumoniae*: *Klebsiella pneumoniae;K. oxytoca*: *Klebsiella oxytoca*; NA: not available.

^a^ Singleton, type harboured by a single strain.

^b^ AMK: amikacin; AZT: aztreonam; CAZ: ceftazidime; CIP: ciprofloxacin; CST: colistin; CTX: cefotaxime; CZT: ceftolozane/tazobactam; ETP: ertapenem; FEP: cefepime; GEN: gentamicin; IPM: imipenem; MEM: meropenem; SXT: trimethoprim/sulfamethoxazole; TGC: tigecycline; TMC: temocillin; TOB: tobramycin; TZP: piperacillin/tazobactam.

^c^ MIC determined by Etest method for temocillin.

^d^ Colistin-resistant MCR-1-positive strain.

On the basis of MIC using EUCAST interpretative criteria, only two (5%; one VIM-producing *K. oxytoca* and one OXA-48-producing *C. koseri*) isolates were susceptible to ertapenem (MIC ≤1 µg/mL), while 23 (61%) OXA-48-positive isolates had imipenem and/or meropenem MICs within the susceptible range (MIC ≤2 µg/mL). All CPE isolates were found resistant to piperacillin/tazobactam and to temocillin with higher temocillin MIC levels (≥ 256 µg/mL) for OXA-48 and VIM producers compared with more variable MIC levels (24--1,024 µg/mL) for KPC- and for NDM-positive isolates. Ceftolozane/tazobactam showed poor activity against CPE since only eight (21%) OXA-48 producers had MIC below the susceptibility cut-off (≤ 1 µg/mL). Tigecycline retained the highest in vitro activity (MIC ≤1 µg/mL) against 95% (36/38) of CPE followed by colistin (MIC ≤2 µg/mL), which was active against 82% (31/38) of the CPE. Interestingly of the seven colistin-resistant CPE isolates in 2015, which were all collected from hospitals (only one detected in the 2012 survey), one OXA-48-positive *E. coli* was found positive for the plasmid-mediated *mcr-1* gene.

Molecular typing by rep-PCR of the 26 carbapenemase-producing *K. pneumoniae* isolates showed their belonging to 19 different DiversiLab (DL) patterns with four clusters (DL types 3, 5, 16 and 23) of more than one isolates ([Table 3](#t3){ref-type="table"}). The three DL type 16 KPC-3 producing isolates were detected in centre C23 and the three DL type 23 OXA-48 producing isolates in centre C17. The other DL types 3 and 5 (all OXA-48 producing) isolates were found in two (one hospital-based and one community-serving) centres each.

Discussion
==========

In this multicentric 2015 survey, we found an overall doubling proportion of 0.55% of clinical CPE among *Enterobacteriaceae* isolates in hospitals compared with 2012 (0.25%). The microbiological analysis confirmed the predominance of *K. pneumoniae* and of OXA-48 among CPE isolates in hospitals and in the community in Belgium. Molecular typing of carbapenemase-producing *K. pneumoniae* confirmed mostly polyclonal distribution although clusters of identical DL types with suspected clonal spread were highlighted as well. Two clusters of different DL types (16 and 23) strongly suggested their intra-hospital clonal dissemination or outbreak. Additionally, the presence of other OXA-48 producing DL types (3 and 5) both in hospitals and in private laboratories that are geographically close (distance \< 30 km) raised the possibility of epidemiological links between the two healthcare sectors. Although no patient history regarding travel or hospitalisation in foreign country was available in this study, data from the national surveillance programme and from the previous prevalence study in 2012 support that the proportion of travel-imported CPE cases should be limited \[[@r17]\].

The strength of our study relies on the use of a standardised methodology performed within the same hospitals between the two study periods to measure the epidemiological parameters with minimal variations due to technical inter-laboratory variability or samples selection bias. The 24 hospital-based laboratories serving tertiary care and general acute-care hospitals of medium to large size were selected for their representative distribution in the three geographical regions (Flanders, Brussels and Wallonia) across Belgium. Only strains isolated from clinical samples were included in the studies in order to limit recruitment bias due to variations in screening strategies for CPE between hospitals. However, our study has some limitations. First, 18% (31/175) of the PCPE isolates detected locally were not referred to the reference laboratory suggesting that the proportion of CPE of 0.55% should be considered as a minimal estimate. Also, the higher proportion of CPE in hospitals in 2015 compared to 2012 could result from the use of EUCAST screening breakpoints theoretically more sensitive than the CLSI susceptibility criteria applied in 2012. In spite of this, the fact that in the present study, only one OXA-48 producing *C. koseri* had the two carbapenems inhibition zones above the CLSI susceptibility cut-offs suggests very rare occurrence of these CPE isolates that poorly expressed carbapenemases.

In addition, the higher proportion of colistin resistance among CPE strains detected in hospitals corroborates with the phenomenon of increasing colistin resistance among CPE isolates observed in Belgium and elsewhere for the past years \[[@r18],[@r19]\]. Furthermore the study evidenced the emergence of the first human MCR-1-positive CPE in Belgian hospitals as well, similar other countries worldwide, where this has also been recently reported in healthcare \[[@r20]-[@r22]\].

In Spain, the latest prospective multicentric study in 83 hospitals performed in 2013 reported a similar overall estimated prevalence of 0.3% of CPE \[[@r4]\] (higher than the 0.04% of metallo-beta-lactamase-producing CPE detected in the previous 35-centres survey in 2009) \[[@r23]\], but 20% of the CPE were of faecal screening origin. The survey showed the same predominance of OXA-48 type CPE, but VIM-producing isolates (the second most frequent) were more widely geographically distributed. Sporadic community-onset infection and post-travel acquisition of CPE had been reported in western countries \[[@r24]-[@r26]\]. In 2016 a case report in Belgium described a household acquisition of OXA-48 producing *K. pneumoniae* in a woman living in the same household than a patient previously infected with a similar CPE, raising the possibility of community spread in low-prevalence areas \[[@r27]\]. However to our knowledge, no specific prospective cross-sectional survey addressing clinical isolates in an ambulatory setting has yet been published.

Regarding the smaller proportion of CNSE (mainly due to the significant decreasing proportion of CNSE among *Enterobacter* spp.) in hospitals in 2015 compared with 2012, no clear explanation could be found. However, a cluster effect could be excluded since the decreased rate of CNSE was documented in 18 of the 24 participating hospitals (data not shown).

In conclusion, this multicentric survey demonstrated a significantly increased proportion of CPE among clinical *Enterobacteriaceae* isolates in hospitals from 2012 to 2015 with an increased proportion of hospitals-based laboratories detecting at least one CPE. Although the proportion of CPE remained globally low, the steady progression and spread of CPE in Belgian hospitals and the emergence of colistin-resistant (including plasmid-mediated *mcr-1* harbouring) strains among CPE raises major concerns. In parallel, the survey in 10 private laboratories highlighted for the first time the establishment of CPE (mainly *K. pneumoniae* species and of OXA-48 type) in an ambulatory setting and suggested possible epidemiological links with hospitals. We therefore believe that repeated national or regional epidemiological studies using standardised protocols at different healthcare levels are essential to measure more accurately the burden of carbapenem resistance.
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